Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

11,864 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A Japanese multicenter phase II study of adjuvant chemotherapy with mFOLFOX6/CAPOX for stage III colon cancer treatment after D2/D3 lymphadenectomy.
Yoshimatsu K, Ishibashi K, Koda K, Yokomizo H, Oda N, Oshiro M, Kato H, Oya M, Nakajima H, Ooki S, Maekawa H, Matsunami T, Tsubaki M, Yamada T, Kobayashi M, Tanakaya K, Yokoyama M, Ishida H. Yoshimatsu K, et al. Among authors: kobayashi m. Surg Today. 2019 Jun;49(6):498-506. doi: 10.1007/s00595-019-1771-y. Epub 2019 Apr 5. Surg Today. 2019. PMID: 30953164 Clinical Trial.
The updated five-year overall survival and long-term oxaliplatin-related neurotoxicity assessment of the FACOS study.
Takeshita E, Ishibashi K, Koda K, Oda N, Yoshimatsu K, Sato Y, Oya M, Yamaguchi S, Nakajima H, Momma T, Maekawa H, Tsubaki M, Yamada T, Kobayashi M, Tanakaya K, Ishida H. Takeshita E, et al. Among authors: kobayashi m. Surg Today. 2021 Aug;51(8):1309-1319. doi: 10.1007/s00595-021-02230-8. Epub 2021 Feb 14. Surg Today. 2021. PMID: 33586034
Multicenter randomized phase II clinical trial of oxaliplatin reintroduction as a third- or later-line therapy for metastatic colorectal cancer-biweekly versus standard triweekly XELOX (The ORION Study).
Matsuda C, Honda M, Tanaka C, Fukunaga M, Ishibashi K, Munemoto Y, Hata T, Bando H, Oshiro M, Kobayashi M, Tokunaga Y, Fujii A, Nagata N, Oba K, Mishima H. Matsuda C, et al. Among authors: kobayashi m. Int J Clin Oncol. 2016 Jun;21(3):566-72. doi: 10.1007/s10147-015-0911-7. Epub 2015 Oct 16. Int J Clin Oncol. 2016. PMID: 26475356 Clinical Trial.
Expressions of 10 genes as candidate predictors of recurrence in stage III colon cancer patients receiving adjuvant oxaliplatin-based chemotherapy.
Kumamoto K, Nakachi Y, Mizuno Y, Yokoyama M, Ishibashi K, Kosugi C, Koda K, Kobayashi M, Tanakaya K, Matsunami T, Eguchi H, Okazaki Y, Ishida H. Kumamoto K, et al. Among authors: kobayashi m. Oncol Lett. 2019 Aug;18(2):1388-1394. doi: 10.3892/ol.2019.10437. Epub 2019 Jun 5. Oncol Lett. 2019. PMID: 31423202 Free PMC article.
Capecitabine and oxaliplatin combined with bevacizumab are feasible for treating selected Japanese patients at least 75 years of age with metastatic colorectal cancer.
Munemoto Y, Kanda M, Ishibashi K, Hata T, Kobayashi M, Hasegawa J, Fukunaga M, Takagane A, Otsuji T, Miyake Y, Nagase M, Sakamoto J, Matsuoka M, Oba K, Mishima H. Munemoto Y, et al. Among authors: kobayashi m. BMC Cancer. 2015 Oct 24;15:786. doi: 10.1186/s12885-015-1712-0. BMC Cancer. 2015. PMID: 26497654 Free PMC article. Clinical Trial.
A phase II study of FOLFOXIRI plus bevacizumab as initial chemotherapy for patients with untreated metastatic colorectal cancer: TRICC1414 (BeTRI).
Shinozaki K, Yamada T, Nasu J, Matsumoto T, Yuasa Y, Shiraishi T, Nagano H, Moriyama I, Fujiwara T, Miguchi M, Yoshida R, Nozaka K, Tanioka H, Nagasaka T, Kurisu Y, Kobayashi M, Tsuchihashi K, Inukai M, Kikuchi T, Nishina T. Shinozaki K, et al. Among authors: kobayashi m. Int J Clin Oncol. 2021 Feb;26(2):399-408. doi: 10.1007/s10147-020-01811-w. Epub 2020 Oct 23. Int J Clin Oncol. 2021. PMID: 33097971 Free PMC article. Clinical Trial.
11,864 results
You have reached the last available page of results. Please see the User Guide for more information.